This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for Johnson & Johnson, SAP & Coca-Cola
by Mark Vickery
Zacks Research Daily spotlights Johnson & Johnson, SAP, and Coca-Cola three global leaders navigating growth opportunities and near-term headwinds.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
by Zacks Equity Research
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
by Kanishka Das
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
by Kinjel Shah
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Take the Zacks Approach to Beat the Markets: Hecla Mining, GE Aerospace & Stride in Focus
by Santanu Roy
Zacks highlights Hecla Mining, GE Aerospace, and Stride as standout performers in a volatile market, driven by earnings trends and stock upgrades.
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
by Ekta Bagri
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
by Zacks Equity Research
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
by Sundeep Ganoria
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
J&J Gears Up for Some Key New Drug Approvals and Launches
by Kinjel Shah
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
Glaukos Builds Dual Growth Engines Amid Market Headwinds
by Zacks Equity Research
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
by Kinjel Shah
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
by Zacks Equity Research
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
by Kinjel Shah
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?
by Kinjel Shah
Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
by Zacks Equity Research
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
by Zacks Equity Research
AbbVie is acquiring Gilgamesh's lead psychedelic drug bretisilocin for up to $1.2B, aiming to expand its depression treatment pipeline
Take the Zacks Approach to Beat the Markets: WisdomTree, SkyWest & PepsiCo in Focus
by Santanu Roy
Zacks highlights gains for WisdomTree, SkyWest, and PepsiCo as its stock strategies deliver strong returns amid market volatility.
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones
by Nalak Das
JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Stryker's Robotics and Global Gains Offset by Macro Concerns
by Zacks Equity Research
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.